Trials / Conditions / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
4 registered clinical trials studyying B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220 | Kami Maddocks | Phase 1 |
| Unknown | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma NCT02481310 | Northwestern University | Phase 1 / Phase 2 |
| Active Not Recruiting | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chron NCT02153580 | City of Hope Medical Center | Phase 1 |
| Completed | Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System NCT01722305 | Mayo Clinic | Phase 1 |